CG
CBIO

Cutler Group’s Crescent Biopharma CBIO Stock Holding History

Cutler Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10
Closed -$5.41K – 4195
2019
Q3 		$4K Buy
+10
New +$6.43K ﹤0.01% 3156
2019
Q2 		– Sell
-1
Closed -$1.2K – 4438
2019
Q1 		$1K Buy
+1
New +$1.15K ﹤0.01% 3673
2018
Q4 		– Sell
-30
Closed -$43K – 4167
2018
Q3 		$43K Sell
30
-13
-30% -$19.7K ﹤0.01% 1698
2018
Q2 		$69K Buy
43
+29
+207% +$49.9K 0.01% 1396
2018
Q1 		$23K Buy
14
+10
+250% +$20.8K ﹤0.01% 2180
2017
Q4 		$6K Buy
4
+1
+33% +$1.32K ﹤0.01% 3482
2017
Q3 		$4K Sell
3
-4
-57% -$4.7K ﹤0.01% 4563
2017
Q2 		$7K Buy
+7
New +$5.78K ﹤0.01% 4515

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cutler Group's CBIO Position: Q4 2019 in Review

Cutler Group sold out of Crescent Biopharma (CBIO) in Q4 2019, closing a stake of 10 shares — an estimated $5.41K sold.

Cutler Group first reported a position in CBIO in Q2 2017 and held it in 8 quarters. The position peaked at $69K in Q2 2018. 78 funds tracked by Wall St. Rank hold CBIO as of Q4 2019.

  • Cutler Group reported no remaining Crescent Biopharma position as of Q4 2019 after selling out during the quarter.
  • Cutler Group sold 10 Crescent Biopharma shares in Q4 2019, an estimated $5.41K.
  • Cutler Group first reported a position in Crescent Biopharma in Q2 2017 and held it in 8 quarters.
  • Cutler Group's Crescent Biopharma position peaked at $69K in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2019.

Based on Cutler Group's 13F filing for Q4 2019, filed 6 Feb 2020.